News

View the replay of our webinar on the place of modeling and artificial intelligence in the development of drug candidates

We participated at the FDA workshop about the development of Best Practices in Physiologically Based Pharmacokinetic Modeling to Support Clinical Pharmacology Regulatory Decision-Making.

Read the interview of our President Bernard Orlandini, along with Marc Essodaigui, CEO of Active Biomarkers and Alexandre Durand-Salmon, CEO of Banook Group.

Translational PK/PD and Model-Informed Drug Development (MIDD) of monoclonal antibodies

The independent medical publication Prescrire.org rewards an outstanding collective effort: the breakthrough drug fexinidazole has been awarded a spot in the prestigious '2020 medicines list'

In vitro-In vivo is a strategic tool in drug developement, discover why!

Consider current and future data regulations when planning studies for your development program.

PhinC Development has set in motion his contingency and continuity plan and implemented a remote-working plan for all employees.

Development of a PBPK model of a molecule to be able to simulate the exposure in the synovial fluid and plasma following an intra-articular administration in adults.